Clinical Trials Logo

Adult Disease clinical trials

View clinical trials related to Adult Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06007092 Recruiting - Clinical trials for Head and Neck Carcinoma

Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer

HPVDCVax
Start date: July 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multicentric double-blind placebo-controlled dose escalation trial of a CD40HVac vaccine (humanized anti-CD40 mAb fused to HPV16 E6/E7 oncoproteins) adjuvanted with poly-ICLC (Hiltonol) in patients with HPV16 oropharyngeal carcinoma with no evidence of residual or recurrent disease after surgery and/or radiochemotherapy. The primary objective is to determine the recommended phase 2 dose (RP2D) of a poly-ICLC(Hiltonol)-adjuvanted CD40HVac vaccine according to the safety and the capacity to elicit immune responses of different doses Two dose levels of poly-ICLC-adjuvanted CD40.HVac will be explored - 1st dose level: CD40.HVac 1.0 mg, with 1.0 mg poly-ICLC - 2nd dose level: CD40.HVac 3.0 mg, with 1.0 mg poly-ICLC The safety data will be reviewed by an IDSMB that will give recommendations.

NCT ID: NCT05817734 Recruiting - Adult Disease Clinical Trials

Human Phenotype Project Study Protocol

Start date: October 1, 2018
Phase:
Study type: Observational

This is a prospective study aimed at recruiting 30,000 individuals, aged 40-70 years old, and following them longitudinally for 25 years with repeated measurements. The basic follow-up frame will include a visit to the Clinical Test Center (CTC) every two years and a phone interview every other year (on uneven years). Sample collection and biobanking will be performed every two years and online questionnaires will be filled out on an annual basis. The primary goals are to study the variation observed across different individuals in disease susceptibility, clinical phenotypes, and therapeutic responses. The study aims at studying the complex interplay and relative contribution of different omics, physiological characteristics and lifestyle on disease pathogenesis and progression and to evaluate how these effects are mediated.

NCT ID: NCT05578872 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Start date: December 16, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma.

NCT ID: NCT04855929 Recruiting - Lung Cancer Clinical Trials

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.

ANV419-001
Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

NCT ID: NCT04643015 Recruiting - Pediatric Disorder Clinical Trials

New Ways of Doing Magnetic Resonance Imaging in Children and Adults

Start date: November 18, 2020
Phase:
Study type: Observational

This study is being done to see how we can prevent problems caused by movement during the MRI scan. Different ways of doing the scan (techniques) will be tested to see if they are practical and can prevent problems related to motion. For example, changes in the timing of the magnetic field and the radio waves will be examined, and at changes in the way a computer is used to process the images. The new techniques will be compared with the techniques that are usually used.